These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1171 related articles for article (PubMed ID: 31553833)

  • 21. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
    Rubin DT; Dotan I; DuVall A; Bouhnik Y; Radford-Smith G; Higgins PDR; Mishkin DS; Arrisi P; Scalori A; Oh YS; Tole S; Chai A; Chamberlain-James K; Lacey S; McBride J; Panés J;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):17-27. PubMed ID: 34798036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
    Danese S; Panaccione R; Feagan BG; Afzali A; Rubin DT; Sands BE; Reinisch W; Panés J; Sahoo A; Terry NA; Chan D; Han C; Frustaci ME; Yang Z; Sandborn WJ; Hisamatsu T; Andrews JM; D'Haens GR;
    Lancet Gastroenterol Hepatol; 2024 Feb; 9(2):133-146. PubMed ID: 38104569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial.
    Atreya R; Peyrin-Biroulet L; Klymenko A; Augustyn M; Bakulin I; Slankamenac D; Miheller P; Gasbarrini A; Hébuterne X; Arnesson K; Knittel T; Kowalski J; Neurath MF; Sandborn WJ; Reinisch W;
    Lancet Gastroenterol Hepatol; 2020 Dec; 5(12):1063-1075. PubMed ID: 33031757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early Symptomatic Improvement After Ustekinumab Therapy in Patients With Ulcerative Colitis: 16-Week Data From the UNIFI Trial.
    Danese S; Sands BE; Abreu MT; O'Brien CD; Bravatà I; Nazar M; Miao Y; Wang Y; Rowbotham D; Leong RWL; Arasaradnam RP; Afif W; Marano C
    Clin Gastroenterol Hepatol; 2022 Dec; 20(12):2858-2867.e5. PubMed ID: 35276329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; van Assche G; Reinisch W; Colombel JF; D'Haens G; Wolf DC; Kron M; Tighe MB; Lazar A; Thakkar RB
    Gastroenterology; 2012 Feb; 142(2):257-65.e1-3. PubMed ID: 22062358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.
    Sandborn WJ; Feagan BG; Wolf DC; D'Haens G; Vermeire S; Hanauer SB; Ghosh S; Smith H; Cravets M; Frohna PA; Aranda R; Gujrathi S; Olson A;
    N Engl J Med; 2016 May; 374(18):1754-62. PubMed ID: 27144850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis.
    Sandborn WJ; Baert F; Danese S; Krznarić Ž; Kobayashi T; Yao X; Chen J; Rosario M; Bhatia S; Kisfalvi K; D'Haens G; Vermeire S
    Gastroenterology; 2020 Feb; 158(3):562-572.e12. PubMed ID: 31470005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.
    Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Feagan BG; Hibi T; Tuttle JL; Klekotka P; Friedrich S; Durante M; Morgan-Cox M; Laskowski J; Schmitz J; D'Haens GR
    Gastroenterology; 2020 Feb; 158(3):537-549.e10. PubMed ID: 31493397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
    Danese S; Vermeire S; Zhou W; Pangan AL; Siffledeen J; Greenbloom S; Hébuterne X; D'Haens G; Nakase H; Panés J; Higgins PDR; Juillerat P; Lindsay JO; Loftus EV; Sandborn WJ; Reinisch W; Chen MH; Sanchez Gonzalez Y; Huang B; Xie W; Liu J; Weinreich MA; Panaccione R
    Lancet; 2022 Jun; 399(10341):2113-2128. PubMed ID: 35644166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.
    Vermeire S; Sandborn WJ; Danese S; Hébuterne X; Salzberg BA; Klopocka M; Tarabar D; Vanasek T; Greguš M; Hellstern PA; Kim JS; Sparrow MP; Gorelick KJ; Hinz M; Ahmad A; Pradhan V; Hassan-Zahraee M; Clare R; Cataldi F; Reinisch W
    Lancet; 2017 Jul; 390(10090):135-144. PubMed ID: 28527704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis.
    Carbonnel F; Colombel JF; Filippi J; Katsanos KH; Peyrin-Biroulet L; Allez M; Nachury M; Novacek G; Danese S; Abitbol V; Bossa F; Moreau J; Bommelaer G; Bourreille A; Fumery M; Roblin X; Reinisch W; Bouhnik Y; Brixi H; Seksik P; Malamut G; Färkkilä M; Coulibaly B; Dewit O; Louis E; Deplanque D; Michetti P; Sarter H; Laharie D; ;
    Gastroenterology; 2016 Feb; 150(2):380-8.e4. PubMed ID: 26632520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Infliximab for induction and maintenance therapy for ulcerative colitis.
    Rutgeerts P; Sandborn WJ; Feagan BG; Reinisch W; Olson A; Johanns J; Travers S; Rachmilewitz D; Hanauer SB; Lichtenstein GR; de Villiers WJ; Present D; Sands BE; Colombel JF
    N Engl J Med; 2005 Dec; 353(23):2462-76. PubMed ID: 16339095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.
    van Vollenhoven RF; Hahn BH; Tsokos GC; Wagner CL; Lipsky P; Touma Z; Werth VP; Gordon RM; Zhou B; Hsu B; Chevrier M; Triebel M; Jordan JL; Rose S
    Lancet; 2018 Oct; 392(10155):1330-1339. PubMed ID: 30249507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.
    Feagan BG; Sands BE; Sandborn WJ; Germinaro M; Vetter M; Shao J; Sheng S; Johanns J; Panés J;
    Lancet Gastroenterol Hepatol; 2023 Apr; 8(4):307-320. PubMed ID: 36738762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial.
    Haifer C; Paramsothy S; Kaakoush NO; Saikal A; Ghaly S; Yang T; Luu LDW; Borody TJ; Leong RW
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):141-151. PubMed ID: 34863330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
    Sandborn WJ; Feagan BG; D'Haens G; Wolf DC; Jovanovic I; Hanauer SB; Ghosh S; Petersen A; Hua SY; Lee JH; Charles L; Chitkara D; Usiskin K; Colombel JF; Laine L; Danese S;
    N Engl J Med; 2021 Sep; 385(14):1280-1291. PubMed ID: 34587385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study.
    Amiot A; Filippi J; Abitbol V; Cadiot G; Laharie D; Serrero M; Altwegg R; Bouhnik Y; Peyrin-Biroulet L; Gilletta C; Roblin X; Pineton de Chambrun G; Vuitton L; Bourrier A; Nancey S; Gornet JM; Nahon S; Bouguen G; Viennot S; Pariente B; Fumery M;
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1039-1046. PubMed ID: 32291786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
    Danese S; Colombel JF; Lukas M; Gisbert JP; D'Haens G; Hayee B; Panaccione R; Kim HS; Reinisch W; Tyrrell H; Oh YS; Tole S; Chai A; Chamberlain-James K; Tang MT; Schreiber S;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):118-127. PubMed ID: 34798038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension.
    Abreu MT; Rowbotham DS; Danese S; Sandborn WJ; Miao Y; Zhang H; Tikhonov I; Panaccione R; Hisamatsu T; Scherl EJ; Leong RW; Arasaradnam RP; Afif W; Peyrin-Biroulet L; Sands BE; Marano C
    J Crohns Colitis; 2022 Aug; 16(8):1222-1234. PubMed ID: 35239968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 59.